메뉴 건너뛰기




Volumn 2015, Issue , 2015, Pages

First use of bedaquiline in a patient with XDR-TB in Singapore

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

EID: 84944041775     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2015-210961     Document Type: Article
Times cited : (3)

References (34)
  • 1
    • 77952542701 scopus 로고    scopus 로고
    • Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis
    • Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
    • (2010) Lancet , vol.375 , pp. 1830-1843
    • Gandhi, N.R.1    Nunn, P.2    Dheda, K.3
  • 4
    • 84902185616 scopus 로고    scopus 로고
    • Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement
    • Lange C, Abubakar I, Alffenaar J, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
    • (2014) Eur Respir J , vol.44 , pp. 23-63
    • Lange, C.1    Abubakar, I.2    Alffenaar, J.3
  • 6
    • 77955872446 scopus 로고    scopus 로고
    • Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
    • Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
    • (2010) Lancet Infect Dis , vol.10 , pp. 621-629
    • Caminero, J.A.1    Sotgiu, G.2    Zumla, A.3
  • 7
    • 84867754043 scopus 로고    scopus 로고
    • Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study
    • Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17.
    • (2012) Lancet , vol.380 , pp. 1406-1417
    • Dalton, T.1    Cegielski, P.2    Akksilp, S.3
  • 8
    • 0028274105 scopus 로고
    • The effect of directly observed therapy on rates of drug resistance and relapse in tuberculosis
    • Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:179-84.
    • (1994) N Engl J Med , vol.330 , pp. 179-184
    • Weis, S.E.1    Slocum, P.C.2    Blais, F.X.3
  • 9
    • 79955610445 scopus 로고    scopus 로고
    • Managing a case of extensively drug-resistant (XDR) pulmonary tuberculosis
    • Phua CK, Chee CBE, Chua APG, et al. Managing a case of extensively drug-resistant (XDR) pulmonary tuberculosis in Singapore. Ann Acad Med Singapore 2011;40:132-5.
    • (2011) Singapore. Ann Acad Med Singapore , vol.40 , pp. 132-135
    • Cbe, P.1    Chee, C.K.2    Apg, C.3
  • 10
    • 10044273203 scopus 로고    scopus 로고
    • Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative
    • Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004;8:1382-4.
    • (2004) Int J Tuberc Lung Dis , vol.8 , pp. 1382-1384
    • Nathanson, E.1    Gupta, R.2    Huamani, P.3
  • 11
    • 84875699280 scopus 로고    scopus 로고
    • Serious treatment related adverse drug reaction among anti-retroviral naive MDR-TB patients
    • Van der Walt M, Lancaster J, Odendaal R, et al. Serious treatment related adverse drug reaction among anti-retroviral naive MDR-TB patients. PLoS ONE 2013;8: e58817.
    • (2013) PLoS ONE , vol.8 , pp. 58817
    • Van Der Walt, M.1    Lancaster, J.2    Odendaal, R.3
  • 12
    • 80053067126 scopus 로고    scopus 로고
    • WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
    • Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
    • (2011) Eur Respir J , vol.38 , pp. 516-528
    • Falzon, D.1    Jaramillo, E.2    Schünemann, H.J.3
  • 13
    • 84880158505 scopus 로고    scopus 로고
    • Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis
    • Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-79.
    • (2013) Eur Respir J , vol.42 , pp. 169-179
    • Migliori, G.B.1    Sotgiu, G.2    Gandhi, N.R.3
  • 14
    • 70349141401 scopus 로고    scopus 로고
    • Treatment outcome of multi-drug resistant tuberculosis: A systematic review and meta-analysis
    • Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcome of multi-drug resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009;4: e6914.
    • (2009) PLoS ONE , vol.4 , pp. 6914
    • Johnston, J.C.1    Shahidi, N.C.2    Sadatsafavi, M.3
  • 15
    • 33847382372 scopus 로고    scopus 로고
    • Outcome of pulmonary multidrug-resistant tuberculosis: A 6-year follow-up study
    • Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-year follow-up study. Eur Respir J 2006;28:980-5.
    • (2006) Eur Respir J , vol.28 , pp. 980-985
    • Chiang, C.Y.1    Enarson, D.A.2    Yu, M.C.3
  • 16
    • 84880162469 scopus 로고    scopus 로고
    • Resistance of fluoroquinolones and second-line injectable drugs: Impact on multi-drug resistant TB outcomes
    • Falzon D, Gandhi N, Migliori GB, et al. Resistance of fluoroquinolones and second-line injectable drugs: impact on multi-drug resistant TB outcomes. Eur Respir J 2013;42:156-68.
    • (2013) Eur Respir J , vol.42 , pp. 156-168
    • Falzon, D.1    Gandhi, N.2    Migliori, G.B.3
  • 18
    • 19944429772 scopus 로고    scopus 로고
    • A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    • Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
    • (2005) Science , vol.307 , pp. 223-227
    • Andries, K.1    Verhasselt, P.2    Guillemont, J.3
  • 19
    • 54449084104 scopus 로고    scopus 로고
    • Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis
    • Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008;283:25273-80.
    • (2008) J Biol Chem , vol.283 , pp. 25273-25280
    • Koul, A.1    Vranckx, L.2    Dendouga, N.3
  • 20
    • 62949223223 scopus 로고    scopus 로고
    • Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue
    • Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 1290-1292
    • Haagsma, A.C.1    Abdillahi-Ibrahim, R.2    Wagner, M.J.3
  • 21
    • 84924420073 scopus 로고    scopus 로고
    • Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort
    • Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015;60:188-94.
    • (2015) Clin Infect Dis , vol.60 , pp. 188-194
    • Guglielmetti, L.1    Le Du, D.2    Jachym, M.3
  • 22
    • 84907377122 scopus 로고    scopus 로고
    • Multidrug-resistant tuberculosis and culture conversion with Bedaquiline
    • Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with Bedaquiline. N Engl J Med 2014;371:723-32.
    • (2014) N Engl J Med , vol.371 , pp. 723-732
    • Diacon, A.H.1    Pym, A.2    Grobusch, M.P.3
  • 23
    • 84872131305 scopus 로고    scopus 로고
    • Approval of novel TB drug celebrated-with restraint
    • Cohen J. Approval of novel TB drug celebrated-with restraint. Science 2013;339:130.
    • (2013) Science , vol.339 , pp. 130
    • Cohen, J.1
  • 25
    • 84944083235 scopus 로고    scopus 로고
    • Compassionate Use Programme of TMC207 in patients with Extensively Drug Resistant(XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection To access, contact RA-CNTNL-JANSSENCU@ITS.JNJ.COM
    • Compassionate Use Programme of TMC207 in patients with Extensively Drug Resistant(XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection. Guidelines for Physicians and Pharmacists. To access, contact RA-CNTNL-JANSSENCU@ITS.JNJ.COM.
    • Guidelines for Physicians and Pharmacists
  • 26
    • 84944083236 scopus 로고    scopus 로고
    • Use of New TB Drugs (accessed 6 Jul 2013)
    • Challenges for Compassionate Use of New TB Drugs. http://www.resisttb.org/?page-id=1371 (accessed 6 Jul 2013).
    • Challenges for Compassionate
  • 27
    • 84861140844 scopus 로고    scopus 로고
    • Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance
    • Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-6.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3271-3276
    • Diacon, A.H.1    Donald, P.R.2    Pym, A.3
  • 28
    • 66649090346 scopus 로고    scopus 로고
    • The diarylquinoline TMC207 for multidrug-resistant tuberculosis
    • Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
    • (2009) N Engl J Med , vol.360 , pp. 2397-2405
    • Diacon, A.H.1    Pym, A.2    Grobusch, M.3
  • 29
    • 84875639613 scopus 로고    scopus 로고
    • Approval of a tuberculosis drug based on a paradoxical surrogate measure
    • Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013;309:1349-50.
    • (2013) JAMA , vol.309 , pp. 1349-1350
    • Avorn, J.1
  • 30
    • 84944083237 scopus 로고    scopus 로고
    • Sirturo (bedaquiline) [product information]. Titusville, NJ: Janssen Therapeutics
    • Sirturo (bedaquiline) [product information]. Titusville, NJ: Janssen Therapeutics, 2012.
    • (2012)
  • 31
    • 84898619017 scopus 로고    scopus 로고
    • Cross resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis
    • Hartkoorn RC, Uplekar S, Cole ST. Cross resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-81.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 2979-2981
    • Hartkoorn, R.C.1    Uplekar, S.2    Cole, S.T.3
  • 32
    • 84904255286 scopus 로고    scopus 로고
    • Acquired resistance of Mycobacterium tuberculosis to bedaquiline
    • Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE 2014;9:e102135.
    • (2014) PLoS ONE , vol.9 , pp. 102135
    • Andries, K.1    Villellas, C.2    Coeck, N.3
  • 33
    • 84891942518 scopus 로고    scopus 로고
    • Bedaquiline in MDR/XDR-TB cases: First experience on compassionate use
    • Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014;43:289-92.
    • (2014) Eur Respir J , vol.43 , pp. 289-292
    • Tiberi, S.1    De Lorenzo, S.2    Centis, R.3
  • 34
    • 84922202908 scopus 로고    scopus 로고
    • A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment
    • Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45:554-5.
    • (2015) Eur Respir J , vol.45 , pp. 554-555
    • Somoskovi, A.1    Bruderer, V.2    Hömke, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.